The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment ...

Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

Planned Parenthood stands to lose a huge portion of its federal funding under President Trump’s “big, beautiful bill,” which could result in the closure of up to 200 clinics, according ...

Olorofim, a novel antifungal agent, shows efficacy and tolerability in patients with invasive fungal diseases with limited ...

Rentosertib, an AI-generated small molecule targeting Traf2- and Nck-interacting kinase, was safe and improved FVC in ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

About an hour after the closing bell, shares of Emergent were trading 6.4% higher, at $7.31. The company's shares ended the day's regular session at $6.87, a gain of 3.7%.

Emergent also secured a $62.4 million contract modification for its botulism antitoxin with the U.S. Department of Health and Human Services, reinforcing its role in medical countermeasures.

New and Unprecedented Survival, Respiratory, and Biomarker Data Prove that NurOwn Helps People with ALS Live Longer and Live ...

The FDA is expected to decide on treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis.